Latest Breaking News On - Nathalie ponnier - Page 6 : comparemela.com

CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd

CSL Behring AG today published the offer prospectus regarding its public tender offer for all publicly held registered shares of Vifor Pharma Ltd., a global specialty pharmaceutical company with leadership in Iron Deficiency, Nephrology & Cardio-Renal Therapies, as indicated in the pre-announcement of the public tender offer published by CSL Limited on 14 December 2021.

United statesVifor pharmaAsia pacificNathalie ponnierJemimah brennanUk financial servicesUs exchangeSwiss stock exchangeGlobal head corporate communicationsSwiss exchangeShareholders of vifor pharma ltdVifor pharma ltdExchange commissionVifor pharma groupUs securities exchangeFresenius medical care

Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®

Vifor Pharma today announced positive findings in the completed phase-IIIb DIAMOND trial of Veltassa® in heart failure patients with either manifest hyperkalemia or with a history of hyperkalemia while treated with renin-angiotensin aldosterone system inhibitor (RAASi) therapy. Veltassa® demonstrated a statistically significant difference versus placebo for the primary endpoint to serum potassium levels in a high risk population.

Vifor pharmaKlaus henning jensenNathalie ponnierJaved butlerSwiss stock exchangeVifor pharma groupGlobal head corporate communicationsSwiss exchangeFresenius medical careChief medical officerPrincipal investigatorExecutive committeePharma groupVifor fresenius medical care renal pharmaMedia contactHead corporate communications

Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®

Press release content from Business Wire. The AP news staff was not involved in its creation.

Vifor pharmaKlaus henning jensenNathalie ponnierJaved butlerSwiss stock exchangeVifor pharma groupGlobal head corporate communicationsSwiss exchangeFresenius medical careChief medical officerPrincipal investigatorExecutive committeePharma groupVifor fresenius medical care renal pharmaBusiness wireHeart failure

Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa

Phase-IIIb trial demonstrates statistically significant outcome on the primary endpoint Largest study to date showing benefit of Veltassa (patiromer) in high risk patient population with heart

Vifor pharmaKlaus henning jensenNathalie ponnierJaved butlerSwiss stock exchangeVifor pharma groupGlobal head corporate communicationsSwiss exchangeFresenius medical careChief medical officerPrincipal investigatorExecutive committeePharma groupVifor fresenius medical care renal pharmaHead corporate communicationsRelations treasury senior manager

Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®

Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Vifor pharmaKlaus henning jensenNathalie ponnierJaved butlerGlobal head corporate communicationsChief medical officerPrincipal investigatorExecutive committee